Parkinson's Disease/Movement Disorders News

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.

The first two female pediatric patients with Rett syndrome have been dosed in an ongoing phase 1/2 trial of investigational AAV9 gene therapy NGN-401, according to the manufacturer.

Health Canada has authorized an amendment to the ongoing REVEAL phase 1/2 trial evaluating an AAV9 investigational gene transfer therapy that expands eligibility to patients with Rett syndrome aged 12 years and older.

A systematic review and meta-analysis of studies involving suicidality among patients with Parkinson’s disease found a high prevalence of suicidal ideation as well as a two times greater risk for suicidal behavior compared with controls.

Vigil Neuroscience Inc. has announced positive interim data from a phase 2 proof-of-concept clinical trial of a monoclonal antibody to treat those suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Octave Bioscience Inc. has received a $10M grant from the Michael J. Fox Foundation for Parkinson’s Research to advance a custom protein biomarker panel to clinically measure Parkinson’s disease activity and progression.

A United Kingdom-based biotech company has announced a global licensing agreement with a California pharma firm to research and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

For older adult males, negative changes in life space were associated with faster cognitive decline and increased risk for neurodegenerative disorders after 7 years, according to research from JAMA Network Open.

A precision therapeutics company announced that the first participant has been dosed in a phase 2 clinical trial of a non-dopamine selective modulator to treat those with early-stage Parkinson’s disease.

Neurocrine Biosciences has announced the resolution of litigation resulting from abbreviated new drug applications brought by companies that wished to market a generic version of Ingrezza before its patent expires.